^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
Guardant360® CDx

Type:
FDA Approved
Related tests:
1year
Clinical • Next-generation sequencing
|
ER (Estrogen receptor)
|
ER positive
|
Guardant360® CDx
1year
Companion diagnostic
|
ER (Estrogen receptor)
|
Guardant360® CDx
1year
Next-generation sequencing
|
Guardant360® CDx • Guardant360 TissueNext™ • Guardant360 Response™ • GuardantREVEAL
over1year
Next-generation sequencing
|
Guardant360® CDx • Guardant360 TissueNext™ • Guardant360 Response™ • GuardantREVEAL
over1year
Clinical • Liquid biopsy • Minimal residual disease
|
Guardant360® CDx • GuardantREVEAL
over1year
Retrospective data • Liquid biopsy • Circulating tumor DNA
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12C • KRAS G12
|
Guardant360® CDx
almost2years
Clinical • Liquid biopsy • Minimal residual disease
|
Guardant360® CDx • GuardantREVEAL
almost2years
Clinical • Liquid biopsy • Minimal residual disease
|
Guardant360® CDx • GuardantREVEAL
almost2years
Clinical • Liquid biopsy • Minimal residual disease
|
Guardant360® CDx • GuardantREVEAL
almost2years
ALK (Anaplastic lymphoma kinase)
|
ALK fusion • ALK mutation • ALK G1202R • ALK V1180L
|
Guardant360® CDx
|
5-fluorouracil • Alecensa (alectinib) • Lorbrena (lorlatinib) • leucovorin calcium
almost2years
Liquid biopsy
|
Guardant360® CDx • GuardantREVEAL
almost2years
Liquid biopsy • Circulating tumor DNA
|
Guardant360® CDx
2years
Clinical • Liquid biopsy • Minimal residual disease
|
Guardant360® CDx